Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Russian Bear who wrote (6226)	1/5/1999 12:54:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 9719

RB, I asked the SUPG IR people for more info on just the issues you raised, and they responded by saying they are sending me a more detailed packet regarding RFS 2000, which I haven't received yet. Here's what I've been able to dig out that's public: SUPG has some sort of right of first refusal for later Stehlin developments. Also, from their license agreement: 4 "COMPOUND" shall mean, **, including pharmacologically acceptable salts thereof and in any pharmaceutically acceptable dosage form. SUPG has the right to develop anything "containing the compound" covered by the patents referenced below. These are the patents referenced in the license agreement between SUPG and Stehlin: U.S. Patent No. 5,352,789, issued OCTOBER 4, 1994, and entitled: METHODS OF PURIFYING CAMPTOTHECIN COMPOUNDS U.S. Patent No. 5,527,913, issued JUNE 18, 1996, and entitled: METHOD FOR PURIFYING CAMPTOTHECIN COMPOUNDS U.S. Patent No. 5,552,154, issued SEPTEMBER 3, 1996, and entitled: METHOD FOR TREATING CANCER WITH WATER-INSOLUBLE S-CAMPTOTHECIN OF THE CLOSED LACTONE RING FORM AND DERIVATIVES THEREOF. U.S. Patent No. 5,608,066, issued MARCH 4, 1997, and entitled: METHODS FOR PURIFYING CAMPTOTHECIN COMPOUNDS. Allowed U.S. Patent Appln. Serial No. 08/474 764, filed JUNE 7, 1995, and entitled: METHOD FOR TREATING CANCER WITH WATER-INSOLUBLE S-CAMPTOTHECIN OF THE CLOSED LACTONE RING FORM AND DERIVATIVES THEREOF. Pending U.S. Patent Appln. Serial No. (UNASSIGNED), filed AUGUST 8, 1997, (Rule 62 Cont. Appln. of USSN 08/470 427) entitled: METHODS FOR PURIFYING 20(S)-CAMPTOTHECIN Pending U.S. Patent Appln. Serial No. 08/767,861, filed DECEMBER 17, 1996, entitled: A METHOD FOR TREATING CANCER WITH WATER-INSOLUBLE S-CAMPTOTHECIN OF THE CLOSED LACTINE RING FORM AND DERIVATIVES THEREOF. Pending U.S. Patent Appln. Serial No. 08/713,392, filed SEPTEMBER 13, 1996, entitled: A METHOD FOR TREATING PANCREATIC CANCER IN HUMANS WITH WATER-INSOLUBLE S-CAMPTOTHECIN OF THE CLOSED LACTONE RING FORM AND DERIVATIVES THEREOF. Maybe we should take further discussion to the SUPG thread. Peter